Drs. Crawford and Hou provide an important clinical introduction to a novel class of hormonal agents that have been under development for several decades for the treatment of advanced and metastatic prostate cancer.
Marc B. Garnick, MD
Advertisement
Articles by Marc B. Garnick, MD
Advertisement
Latest Updated Articles
- Important Considerations in LHRH Antagonist Therapy for Prostate Cancer
Published: June 9th 2009 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Issues CRL for Dasatinib in CML/ALL
2
Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer
3
FDA Accepts Resubmission of BLA for RP1/Nivolumab in Advanced Melanoma
4
Patient With RRMM, Cytopenias, COPD, and Progressive Bone Disease
5
